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Introduction
In recent years, many medical centres across the USA, Canada
and Europe have noted an increase in the incidence and sever-
ity of Clostridium difﬁcile infections (CDI). This coincided with
the emergence of a hypervirulent toxinotype III BI/NAP1/027
strain of C. difﬁcile with increased toxin production [1]. C. difﬁ-
cile infections are generally associated with diarrhoea and
colitis, whereas severe infections present with megacolon,
perforation or septic shock. Infections outside the colon are
considered to be rare, often occurring in patients who have
had a prior colectomy [2–5]. Nonetheless, more cases of
enteric CDI have been published in the last few years [6–13].
We report the ﬁrst case, to our knowledge, of C. difﬁcile
enteritis proven to be caused by the hypervirulent BI/NAP1/
027 strain in a patient without previous abdominal surgery,
and review the recent experience of two Canadian academic
centres with small bowel CDI.
Index Case and Methods
In June 2005, during a C. difﬁcile outbreak caused by the BI/
NAP1/027 clone [14], a 61-year-old man was admitted to
Hoˆpital Maisonneuve-Rosemont (HMR) for radical prosta-
tectomy with lymphadenectomy for a prostatic adenocarci-
noma. No prior antibiotic use was reported and no
perioperative antimicrobial prophylaxis was given. The post-
operative period was uneventful and the patient was dis-
charged on day 4. He was readmitted on the same day for
an acute episode of fever, dyspnoea and hypotension. He
was intubated and transferred to the intensive care unit
(ICU). A thoracic angioscan ruled out pulmonary embolism.
C. difﬁcile colitis was suspected based on an episode of
severe diarrhoea at home but, because of ileus, no stools
were available for testing after admission. He was given oral
(500 mg every 6 h) and intrarectal vancomycin (1 g every
6 h for ﬁve doses) in association with intravenous metroni-
dazole. Ticarcillin/clavulanate was added for possible aspira-
tion at the time of intubation. The patient died 2 days later
of multiple organ failure. At autopsy, pseudomembranes
were found in the ileum but not in the colon. Histology
was concordant with C. difﬁcile pseudomembranes. Because
of the suspected diagnosis, the biopsy specimens were
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cultured aerobically on blood, chocolate and MacConkey
agar and anaerobically on Brucella and CCFA agar (Cyclo-
serine Cefoxitin Fructose Agar; Quelab Laboratories, Que-
bec, Canada) as previously described [14]; toxigenic
C. difﬁcile was isolated from the ileal tissue, but not from
the colonic tissue. Strain typing conﬁrmed the presence of
the hypervirulent BI/NAP1/027 clone [15]. Both specimens
were negative for Staphylococcus aureus by culture.
This prompted us to review all patients who had evidence
of ileal CDI, from January 2003 to December 2007, at two
hospitals in the province of Quebec: HMR, a 545-bed univer-
sity-afﬁliated tertiary-care hospital, in Montreal, and the Cen-
tre Hospitalier Universitaire de Sherbrooke (CHUS), a 685-
bed hospital, in Sherbrooke. All autopsies conducted during
the study period were reviewed for evidence of small bowel
CDI. The microbiology results for all patients who had
undergone total colectomy for any reason were also
reviewed to look for evidence of CDI after surgery. We
considered only those patients for whom no colonic/rectal
tissue was left in place after the procedure. A case was
deﬁned as: (i) pseudomembranes visualized in the lumen of
the small intestine at surgery or autopsy in a patient with a
positive C. difﬁcile toxin assay or (ii) a positive C. difﬁcile toxin
assay in a patient without residual colon who experienced
higher stool output.
During the study period, stools from hospitalized patients
submitted to the HMR microbiology laboratory for C. difﬁcile
toxin detection were ﬁrst tested with the Triage Micro C. dif-
ﬁcile panel (Biosite Diagnotics, San Diego, CA, USA). Speci-
mens that were glutamate dehydrogenase (GDH) positive
and toxin A positive were reported as positive for the pres-
ence of C. difﬁcile toxin. Specimens that were GDH positive
but toxin A negative were retested with a cytotoxin assay
on Vero cells using the C. difﬁcile Toxin/Antitoxin Kit (Tech-
Lab, Blackburg, VA, USA). At CHUS, the cell culture cyto-
toxin assay was performed on all stools sent for toxin
detection. Toxigenic bacterial culture was available at both
sites for epidemiologic surveillance and research purposes
only [14].
Results
A review of 904 autopsy reports and all microbiology
records of 145 patients who had had total colectomy in
either hospital revealed the presence of three and eight addi-
tional cases, respectively, for a total of 12 cases.
As shown in Table 1, the median age of patients was
72 years (range 21–81 years) and six (50%) were male. Ten
patients (83%) had undergone intestinal surgery prior to ileal
CDI. Of those patients, ﬁve had undergone a colectomy
for a previous episode of CDI, a median of 29 days (range
16–363 days) prior to their ileal CDI episode.
The diagnosis of ileal CDI was conﬁrmed in nine cases
with microbiological testing of stools from ileostomy or ileal
tissue. Three other patients had a positive toxin result on a
stool from the rectum or ileal reservoir but with radiological
and/or pathological evidence of ileal involvement. The median
leukocyte count at the moment of diagnosis of ileal CDI was
11.4 · 109 cells/L (range 1.5–66.2 · 109 cells/L).
Among the four patients diagnosed with C. difﬁcile ileitis
at autopsy, patients HMR-2 and HMR-3 underwent a total
colectomy for the current episode of CDI and died in the
immediate postoperative period. The diagnosis of ileal CDI
was made at autopsy. Patient HMR-4 developed severe
CDI after cysto-prostatectomy, died on the day after diag-
nosis, and was also found to have ileal CDI at autopsy.
The other patient is the index case. All four patients had
histological ﬁndings concordant with the macroscopic
observations.
Among the eight cases diagnosed primarily by virtue of
the absence of the colon, patients HMR-5, HMR-9 and
CHUS-3 had had a colectomy because of CDI, and
received, respectively, 10, 8 and 12 days of antibiotics
active against C. difﬁcile after surgery. Their ileal stool
specimen was positive for C. difﬁcile toxin 24, 21 and
16 days after surgery, respectively. Patient HMR-5 was re-
admitted to the ICU 23 days after colectomy for vomiting,
high stool output and leukocytosis (45.0 · 109 cells/L). A
computed tomography showed moderate distension of the
ileum. No other pathogen was isolated. The patient died
10 days later despite treatment with oral and intravenous
metronidazole and oral vancomycin. No autopsy was con-
ducted. Patient HMR-9 was treated with oral vancomycin
because of high stool output and patient CHUS-3
improved without any treatment.
Patients HMR-7 and CHUS-1 had also had a colectomy
because of CDI, 4 months and 1 year prior to ileal CDI,
respectively. Both presented with higher stool output from
their ileostomy and with a positive C. difﬁcile toxin assay.
Both improved on treatment.
Patients HMR-6, HMR-8 and CHUS-2 had had a colecto-
my because of inﬂammatory bowel disease and presented
with diarrhoea. Patient HMR-6 underwent a computed
tomography that showed thickening of the small bowel
mucosa. All patients had positive toxin assays and responded
to metronidazole treatment.
Most patients had severe CDI; seven (58%) were admitted
to the ICU because of their C. difﬁcile infection and ﬁve
(42%) died.
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Discussion
C. difﬁcile, the main aetiologic agent of health care-associated
diarrhoea, is considered to be essentially a colonic pathogen.
Until the year 2000, only nine cases of ileal involvement with
C. difﬁcile had been published [2–5,16–20]. During the last
8 years, 14 additional cases have been reported [6–13].
A review of previous cases of ileal CDI showed that 19
out of 23 patients had had prior abdominal surgery, 15 of
whom had a partial or total colectomy. Twelve cases were
early postoperative complications, occurring <90 days after
surgery. In our series, among those patients who had had a
previous colectomy, ﬁve developed early postoperative ileal
CDI and four developed late postoperative ileal CDI. Tsu-
taoka et al. [16] hypothesized that, after colectomy, the
mucosa of the small bowel could become colonized with
organisms more characteristic of the colon. This could be
explained by loss of the mechanical action of the ileocaecal
valve [19] or by morphological changes in the small intestinal
epithelium when the faecal ﬂow is altered [5].
However, this cannot explain all cases of ileal CDI because
not all of the patients reported had undergone a previous
colectomy, and some of them still had their ileocaecal valve
in place. Another hypothesis would be that C. difﬁcile is more
frequently involved in small bowel infections than previously
considered, but that limited access to that organ makes the
anatomical diagnosis difﬁcult. Testore et al. [21] have shown
at autopsy that C. difﬁcile colonized the jejunum of three of
100 patients who had died of nongastrointestinal causes, a
prevalence of colonization that is similar to that reported in
some series of stool carriage of C. difﬁcile in healthy adults.
C. difﬁcile toxins A (TcdA) and B (TcdB) bind to cellular
receptors present on many cell types and inhibit small GTP-
ases such as Rho, Rac and Cdc42 that are found in many
eukaryotic cells [22]. Rabbit ileal loops exposed to toxin A
will generate pathological ﬁndings similar to those seen in
human CDI [23] and two of our patients without prior intes-
tinal surgery had pseudomembranes in their ileum. Taken
together, these facts support the idea that a process similar
to what happens in infection of the colon can occur in the
human small bowel.
It has been postulated that ileal CDI may be associated
with worse outcomes than CDI of the colon [5,6]. Should
C. difﬁcile enteritis indeed be more frequent than previously
thought, it is plausible that only severe cases (i.e. those
requiring surgery or found at autopsy) would be diagnosed
and reported. Alternatively, even if C. difﬁcile can be found in
the small bowel and cause disease, other factors might nor-
mally prevent the production of enough toxin at that site,
except in the presence of a hypervirulent strain. Testore
et al. [3] implicated high levels of toxin A as a mechanism for
ileal involvement in C. difﬁcile infections; the BI/NAP/027
strain, the causal agent of the recent epidemics in Canada, is
known to produce higher amounts of TcdA than other
strains [1]. This strain also produces binary toxin CDT, a
toxin that is known to be enterotoxic in an ileal loop assay,
but whose exact role in the pathogenesis of CDI is still
under investigation [24]. Another explanation could be
related to the adhesion of C. difﬁcile to the intestine, a step
that may be important in the development of disease. Keel
and Songer [25] have hypothesized that the region of the
intestine in which C. difﬁcile can proliferate could explain the
difference in the distribution of lesions in CDI caused by dif-
ferent species. In a neonatal pig model, they showed that the
intensity of TcdA binding was not correlated with the loca-
tion of the naturally occurring lesions (the caecum and the
colon), but that experimental gavage of pigs with this toxin
produced much more severe lesions in the small intestine
[26]. It might be possible that the BI/NAP/027 strain can col-
onize the small intestine more easily than previous strains.
Both hypotheses could in turn explain why we found so
many cases in approximately 5 years. During the study per-
iod, more than two-thirds of recovered isolates of C. difﬁcile
in our hospitals belonged to the toxin-hyperproducing strain
[1,14]. Among those patients infected with the BI/NAP1/027
strain, there was a higher case-fatality ratio after adjustment
for confounding factors such as age and the burden of
chronic co-morbidities [14]. With a high prevalence of the
BI/NAP1/027 strain at our institutions, many of our patients
could have been infected by the epidemic strain, but only
one had a proven infection as a result of this epidemic
strain.
The contribution of C. difﬁcile ileitis to the overall clinical
picture of our patients remains uncertain. In three of our
autopsy cases, the ileal inﬂammation was more severe than
the colon pathology and probably contributed to the fatal
outcome. For the six patients whose ileal CDI was diagnosed
by virtue of the prior surgical removal of the colon with
C. difﬁcile toxin found in the ileostomy output (HMR-7, 8, 9
and CHUS-1, 2, 3), causality is less certain. C. difﬁcile toxin
was sought because of a perception of an abnormal output,
but the presence of ileal pseudomembranes was not docu-
mented endoscopically. Nonetheless, this supports the
assumption that C. difﬁcile can be found in the ileum and that
the spectrum of disease may be broader than originally con-
sidered. The fact that all but one of the patients received
treatment for CDI, and improved, also strengthens the
assumption that C. difﬁcile may have been responsible for
their symptoms.
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There are limitations to this study. First, the overall sever-
ity of cases might be explained to some extent by the study
design: by looking at autopsy reports, we were biased
towards identifying more severe cases. We tried to circum-
vent this problem by looking at patients who had had a co-
lectomy because we thought that this would allow us to ﬁnd
the less severe cases. Second, because the study was retro-
spective, it was impossible to document ileal pseudomem-
branes with endoscopy. Third, because only specimens from
the index case were cultured, it was impossible to evaluate
whether the BI/NAP1/027 strain was indeed responsible for
all cases.
In conclusion, although still rare, ileal involvement in C. dif-
ﬁcile infections appears to be reported with an increasing fre-
quency. To our knowledge, ours is the largest case series of
small bowel CDI reported. Over a 5-year period, 12 cases
were identiﬁed. The hypervirulent BI/NAP1/027 strain might
be responsible for some of these observations. It is impor-
tant to raise awareness about this entity to ensure that
patients are diagnosed correctly and that further prospective
studies are conducted to address the exact signiﬁcance of C.
difﬁcile infections of the small bowel. C. difﬁcile toxin should
be sought in the stools of patients who have had a colecto-
my when they are exposed to antibiotics and when their
ileostomy output volume dramatically changes from normal.
Gastroenterologists and/or colorectal surgeons should be
encouraged to document the presence or absence of ileal
inﬂammation in patients found to have C. difﬁcile toxin in
their ileostomy output or in patients with severe CDI, such
as those who need colectomy. Those with possible ileal CDI
should be treated with oral vancomycin, which will reliably
result in therapeutic concentrations in the small bowel, in
contrast with metronidazole[27].
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